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Abstract
Background: The primary aims of this study were (i) to determine the quantity and pattern of antibiotic use in
Austria between 1998 and 2007 and (ii) to analyze antibiotic resistance rates in relation to antibiotic consumption
in important clinical situations in order to provide data for empirical therapeutic regimens for key indications.
Methods: Consumption data and resistance data were obtained via the Austrian surveillance networks European
Antimicrobial Resistance Surveillance System (EARSS) and European Surveillance on Antimicrobial Consumption
(ESAC). The EARSS collects data on isolates from blood and cerebrospinal fluid obtained predominantly in the
hospital setting. The Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD)
measurement units were assigned to the data. The number of DDDs and packages per 1,000 inhabitants (PID)
were used to calculate the level of antibiotic consumption. Antibiotic resistance was expressed in resistance rates,
i.e., the percentage of resistant isolates compared to all isolates of one bacterial species.
Results: The overall antibiotic consumption measured in DIDs increased by 10% between 1998 and 2007,
whereas PIDs decreased by 3%. The consumption of substances within the drug utilization 90% segment
(measured in PID) increased for ciprofloxacin (+118.9), clindamycin (+76.3), amoxicillin/clavulanic acid (+61.9%),
cefpodoxime (+31.6), azithromycin (+24.7); and decreased for erythromycin (-79.5%), trimethoprim (-56,1%),
norfloxacin (-48.8%), doxycycline (-44.6), cefaclor (-35.1%), penicillin (-34.0%), amoxicillin (-22.5), minocycline (-
21.9%) and clarithromycin (-9.9%). Starting in 2001, an increase in the percentage of invasive E. coli isolates
resistant to aminopenicillins (from 35% to 53%), fluoroquinolones (from 7% to 25.5%) and third-generation
cephalosporins (from 0% to 8.8%) was observed. The percentage of nonsusceptible or intermediate penicillin-
resistant pneumococcal isolates remained stable over this time period at around 5%. For macrolides, the rate of
resistant isolates increased from 5% to 12.8%, with a peak in 2005 at 14.7%.
Conclusion: The Austrian resistance data can not explain the fundamental change in prescribing practice. The
more frequent use of ciprofloxacin has most likely contributed to rising resistance rates in E. coli in Austria.
Penicillin G is still a highly effective substance for the treatment of invasive infections caused by pneumococci.
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Background
Antibiotic resistance has become an important public
health issue in the last decade. To better understand
national, regional, and local trends, it is important to crit-
ically assess national data on antibiotic consumption.
Moreover, given the increasing rates of antibiotic resist-
ance, it is important to be aware of the relationship
between antibiotic consumption and emergence of resist-
ance. Since only a very small number of new antibiotics
are under development, physicians can not rely on new
drugs alone to treat infections caused by multidrug-resist-
ant bacteria, but must also introduce policies to reduce the
emergence and spread of resistant bacteria [1].
With the launch of the European projects EARSS (Euro-
pean Antimicrobial Resistance Surveillance System, 1999)
and ESAC (European Surveillance on Antimicrobial Con-
sumption, 2001), comprehensive surveillance of antibi-
otic resistance and consumption on a national level began
in Austria 10 years ago. Since then, the quality and quan-
tity of data has steadily improved. Now it is possible to
draw conclusions and shed some light on the actual situ-
ation.
The primary aims of this study were (i) to determine the
quantity and pattern of antibiotic use in Austria between
1998 and 2007 and (ii) to analyze antibiotic resistance
rates in relation to antibiotic consumption in important
clinical situations in order to provide data for empirical
therapeutic regimens for key indications.
Methods
Consumption data
In Austria, antibiotics are available only with a prescrip-
tion issued by a physician and are dispensed by pharma-
cies. Antibiotics account for only about 3.7% of the total
drug budget and therefore play a minor role in the surveil-
lance of drug prescribing in ambulatory care. For physi-
cians in ambulatory care, the few existing restrictions in
antibiotic prescribing are limited mainly to expensive
antibiotics such as gentamycin, tobramycin, telithromy-
cin and linezolid.
Quarterly data from the ambulatory care (AC) sector were
obtained from the Main Association of Austrian Social
Security Institutions (HV) for the purpose of data collec-
tion carried out by the European Surveillance of Antimi-
crobial Consumption (ESAC). The HV is responsible for
collecting information on all drugs dispensed and reim-
bursed by the social health insurance institutions. In Aus-
tria, there is no private market for antibiotics and only a
very small amount, estimated to be 2%, of antibiotics are
cheaper than the reimbursement fee and are therefore not
included in the national data. Only a few small packages
of tetracycline and trimethoprim are cheaper than the
reimbursement fee.
Units of measurement and approach of analysis
The Anatomical Therapeutic Chemical (ATC) classifica-
tion and the Defined Daily Dose (DDD) measurement
units (ATC/DDD version 2007) were assigned to the data.
Besides analyzing the consumption data in DDDs per
1,000 inhabitants per day (DID), the number of packages
per 1,000 inhabitants per day (PID) was used as a proxy
for prescriptions to measure time trends on a national
level, thereby allowing international comparison. Despite
the merits of the ATC/DDD classification system, there is
a need for a simple and unbiased unit of measurement
that disregards changes in package size or changes in dos-
ing [2]. Therefore, prescriptions per 1,000 inhabitants per
day were calculated and analyzed in the present study.
After assigning the ATC/DDD classification, the 90% drug
utilization (DU90; i.e., substances constituting 90% of
consumption), expressed as PID and DID, was calculated
for all substances to identify those most frequently used.
These substances were then further analysed comparing
DID and PID as well as evaluating consumption trends
over time.
Resistance data
The Austrian EARSS has the most comprehensive collec-
tion of data on antibiotic resistance in Austria and consists
of a voluntary network of 41 microbiology laboratories
covering more than 85% of all Austrian acute care hospi-
tal beds. The number of laboratories participating in this
study increased steadily from 10 in 2000 to 41 in 2007.
For this study, Pneumococci and E. coli strains causing
invasive infections were selected as key organisms for
measuring antibiotic resistance. E. coli is the leading cause
of community-onset bacteraemia, whereby 68% of infec-
tions are community-acquired, 19% are hospital-
acquired, and 13% are healthcare-associated (e.g., cathe-
terised patients), but it can still be used as an indicator for
antibiotic resistance levels and trends in outpatient care,
even if it is measured via hospital data [3]. This also holds
true for invasive pneumococcal disease. Data on antibi-
otic resistance of E. coli against aminopenicillins, fluoro-
quinolones and third-generation cephalosporines, as well
as data on resistance of pneumococci against penicillin
and macrolides are routinely collected in accordance with
the EARSS protocol [4]. Once a year, an external quality
assurance exercise organized by EARSS und provided by
the United Kingdom National External Quality Assess-
ment Service (UKNEQAS) is performed in all laboratories
reporting to EARSS in Austria [5].
Antibiotic resistance was expressed in resistance rates, i.e.,
the percentage of resistant isolates compared to all isolates
of one bacterial species. The designation of nonsuscepti-
bility was based on the Clinical and Laboratory Standards
Institute breakpoints according to the most recent docu-
ment available at the time. Since breakpoints for the anti-
biotics analyzed in this study have not changed over theBMC Infectious Diseases 2009, 9:61 http://www.biomedcentral.com/1471-2334/9/61
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relevant time period, resistance data remain current [6].
According to a consensus decision in 1998, all Austrian
microbiology laboratories use CLSI (Clinical Laboratory
Standards Institute, Wayne, Pa., USA, formerly NCCLS,
National Committee on Clinical Laboratory Standards)
standards for interpreting susceptibility test results. The
methods used are the disk diffusion test according to CLSI
(Performance Standards for Antimicrobial Disk Suscepti-
bility Tests, Document M02 in the respective edition), the
E-test (AB Biodisk, Solna, Sweden), both on Mueller-Hin-
ton agar, and the automated systems Vitek 2 (bioMérieux,
Marcy l'Etoile, France), Phoenix (BD, Franklin Lakes, NJ,
USA) and MicroScan WalkAway (Siemens Healthcare
Diagnostics, Eschborn, Germany).
Results
Antibiotic consumption
The overall antibiotic consumption measured in DIDs
showed an increase of 10% between 1998 and 2007,
whereas PIDs decreased by 3%. The number of DIDs
ranged from 12.3 – 14.6 and the number of PIDs ranged
from 1.7 – 2.0 over time. In the latest available data for
2007, prescriptions for betalactams, macrolides, quinolo-
nes, tetracyclines and others accounted for 48.2%, 30.9%,
12.3%, 5.1%, and 3.5%, respectively. In the DID ranking,
the most frequently used substance class was betalactams
(7.92 DID) followed by macrolides (3.5 DID), quinolo-
nes (1.43 DID), tetracyclines (1.27 DID), sulfonamides/
trimethoprim (0.31 DID), and others (0.185 DID).
The core group of substances was determined using the
DU90 values for 1998 and 2007. An overview of the sub-
stances included in the DU90 segment of 1998 and 2007
as well as PID and DID values and changes of PID and
DID in percent of 1998 are displayed in Table 1. The con-
sumption of substances within the DU90 segment, meas-
ured in PID, increased for ciprofloxacin (+118.9),
clindamycin (+76.3), amoxicillin/clavulanic acid
(+61.9%), cefpodoxime (+31.6), and azithromycin
(+24.7); and decreased for erythromycin (-79.5%), tri-
methoprim (-56.1%), norfloxacin (-48.8%), doxycycline
(-44.6), cefaclor (-35.1%), penicillin (-34.0%), amoxicil-
lin (-22.5), minocycline (-21.9%), and clarithromycin (-
9.9%). In 1998, trimethoprim, erythromycin, ofloxacin
and norfloxacin were included in the DU90 list; moxi-
floxacin was not included in the DU90 list because it was
introduced on the market in 2001. In 2007, its consump-
tion accounted for 2.4% of the total amount used
(expressed in PID).
When examining consumption over time, it is noteworthy
that there is a considerable divergence between DID and
PID values for clarithromycin, amoxicillin, amoxicillin/
clavulanic acid, clindamycin, azithromycin, and doxycy-
cline. To explain this discrepancy, the average grams of
substance per package were determined. The analysis
showed that indeed, the average package size of these sub-
stances has changed over the study period. For example,
the average grams per package of amoxicillin/clavulanic
acid increased from 5.1 to 9 grams during this time.
Antibiotic resistance
Since 2001, a continuous and steep increase in the per-
centage of invasive E. coli isolates resistant to aminopeni-
Table 1: DID and PID values of 1998 and 2007 as well as change in percent of 1998
Year of DU90 ATC code/Substance name 1998 PID 2007 PID ΔPID 1998 DID 2007 DID ΔDID
1998 & 2007 J01AA02 doxycycline 0.11 0.06 -44.63 1.43 1.01 -29.20
1998 & 2007 J01AA08 minocycline 0.04 0.03 -21.87 0.33 0.26 -20.84
1998 & 2007 J01CA04 amoxicillin 0.12 0.09 -22.51 1.15 1.45 26.36
1998 & 2007 J01CE02 phenoxymethylpenicillin 0.19 0.12 -34.01 1.49 1.01 -32.59
1998 & 2007 J01CR02 amoxicillin und enzyme inhibitor 0.24 0.39 61.86 1.65 3.74 126.74
1998 & 2007 J01DB01 cefalexin 0.06 0.05 -7.41 0.29 0.28 -2.81
1998 & 2007 J01DC02 cefuroxime 0.02 0.03 98.15 0.20 0.41 106.56
1998 & 2007 J01DC04 cefaclor 0.09 0.06 -35.13 0.34 0.20 -40.27
1998 & 2007 J01DD08 cefixime 0.09 0.08 -10.06 0.47 0.43 -9.99
1998 & 2007 J01DD13 cefpodoxime 0.05 0.07 31.63 0.23 0.32 36.24
1998 J01EA01 trimethoprim 0.05 0.02 -56.08 0.32 0.20 -37.70
1998 J01FA01 erythromycin 0.04 0.01 -79.45 0.21 0.05 -75.60
1998 & 2007 J01FA09 clarithromycin 0.28 0.26 -9.90 1.89 2.04 7.96
1998 & 2007 J01FA10 azithromycin 0.10 0.13 24.70 0.44 0.48 7.46
1998 & 2007 J01FF01 clindamycin 0.07 0.13 76.73 0.28 0.57 106.95
1998 J01MA01 ofloxacin 0.03 0.01 -62.18 0.22 0.08 -63.45
1998 & 2007 J01MA02 ciprofloxacin 0.06 0.13 118.88 0.35 0.74 110.11
2007 J01MA14 moxifloxacin 0.00 0.05 - 0.00 0.30 -
1998 J01MA06 norfloxacin 0.06 0.03 -48.83 0.43 0.20 -45.78
Δ change in PID or DID in % of 1998BMC Infectious Diseases 2009, 9:61 http://www.biomedcentral.com/1471-2334/9/61
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cillins (from 35% to 53%), fluoroquinolones (from 7% to
25.5%) and third-generation cephalosporins (from 0% to
8.8%) was observed. In 2001, 61.1% of all isolates were
susceptible to all four substance classes, but this number
decreased to 41.9% in 2007. In addition, the rate of iso-
lates resistant to more than one substance class increased
from 8.1% in 2001 to 25.5% in 2007. The percentage of
invasive E. coli resistant to all three substances increased
from 1% to 8% over time. The percentage of nonsuscepti-
ble or intermediate penicillin resistant pneumococcal iso-
lates remained stable over time at around 5%. In 2007,
five isolates showed high-level resistance to penicillin. For
macrolides, the rate of resistant isolates increased from
5% to 12.8%, with a peak in 2005 at 14.7%. The resist-
ance rates for invasive E. coli and Pneumococci are shown
in Figures 1, 2 and 3.
Discussion
Analyzing antibiotic consumption data is a difficult task.
Although it is agreed that unified classification systems
and measurements such as DDDs are needed for interna-
tional comparison, there are still unresolved issues con-
cerning how to measure change over time within one
country accurately and how to retrieve the values closest
to reality. By looking only at consumption expressed in
DDD, change in the consumption patterns could be over-
as well as underestimated if the average grams per package
change over time. The use of packages as a proxy for pre-
scriptions seems to be appropriate to avoid this bias.
Despite all technical difficulties, surveillance of antimi-
crobial use is a key strategy to monitor appropriateness of
antimicrobial therapy. In Austria, consumption is rela-
tively low (12.3 – 14.6 DID) in comparison to other Euro-
pean countries (mean DID 19.04) and the USA (24.9
DID) [7]. In Europe, the level of consumption ranges
from 9.8 DID in The Netherlands to 33.4 in Greece. In the
past ten years, the level of antibiotic consumption has not
changed substantially, regardless of the measurement
used. Compared to other European countries, Austria
ranges among the low consumer countries such as The
Netherlands, Germany and Estonia for penicillins as well
as for total consumption [8,9]. With regard to cepha-
losporins and fluoroquinolones, Austria ranges mid-field
in Europe, meaning a relatively high proportion of fluor-
oquinolones and cephalosporin compared to other Euro-
pean countries [10,11]. Although the total volume of
consumption has not changed over time, the composition
of substances did. There was a considerable increase in the
consumption of fluoroquinolones, betalactams and a
decrease in the use of tetracyclines and sulfonamide/tri-
methoprim. The level of consumption of macrolides did
not change over time.
Analysis of the consumption of particular substances
shows that especially the use of ciprofloxacin and amoxi-
cillin/clavulanic acid has increased dramatically, indicat-
ing that substances with a lower selective pressure, such as
penicillin, have been exchanged for amoxicillin/clavu-
Percentage of resistance to fluoroquinolones, third-generation cephalosporines and aminopenicillins in E. coli isolated from  blood (2001: n = 260; 2007: n = 2,606) Figure 1
Percentage of resistance to fluoroquinolones, third-generation cephalosporines and aminopenicillins in E. coli 
isolated from blood (2001: n = 260; 2007: n = 2,606).
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Percentage of high-level and low-level resistance to penicillin in invasive Pneumococci in Austria 2000–2007 (2000: n = 63;  2007: N = 323) Figure 2
Percentage of high-level and low-level resistance to penicillin in invasive Pneumococci in Austria 2000–2007 
(2000: n = 63; 2007: N = 323).
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Percentage of high-level and low-level resistance to macrolides in invasive Pneumococci in Austria 2000–2007 
(2000: n = 63; 2007: N = 323).
0
5
10
15
20
25
2000 2001 2002 2003 2004 2005 2006 2007
year
p
e
r
c
e
n
t
% resistant
% intermediate resistantBMC Infectious Diseases 2009, 9:61 http://www.biomedcentral.com/1471-2334/9/61
Page 6 of 7
(page number not for citation purposes)
lanic acid [8]. The percentage of use of moxifloxacin has
increased continuously, from 15% in 2004 to 20% of total
fluoroquinolone use in 2007 [11]. In 2001, the patent for
ciprofloxacin expired and since then, the number of pre-
scriptions has more than doubled. Interestingly, the
increase of ciprofloxacin prescriptions is almost equal to
the magnitude of the decrease in prescriptions of nor-
floxacin and sulfonamide/trimethoprim together, indicat-
ing a switch in the therapy of urinary tract infections in
primary care. The increased use of fluoroquinolones and
the traditionally frequent use of third-generation cepha-
losporines [10,12] are very likely to cause and promote
the incidence of resistant microorganisms in Austria [13].
It is remarkable that the resistance rate of invasive E. coli
to fluoroquinolones rose from 7% in 2001 to 25.5% in
2007; resistance to third-generation cephalosporins also
rose from 0% in 2000 to 7% in 2007. Ena et al. showed
that the use of fluoroquinolones and urinary catheterisa-
tion are independent risk factors for the acquisition of uri-
nary tract infections with ESBL-producing E. coli [14].
This and other evidence in the literature suggest a close
association between the use of fluoroquinolones and the
increase in the incidence of multidrug-resistant E. coli
[15,16].
Routinely-collected surveillance data on antibiotic resist-
ance usually do not include those from uncomplicated
urinary tract infections. Due to the lack of representative
surveillance data from urinary samples, data on invasive
infections must be used for the development of empirical
therapy regimens, although resistance might be overesti-
mated, since 32% of E. coli bacteraemia cases are health-
care associated or even hospital-acquired. With regard to
complicated urinary tract infections, there is evidence
from the US that first-line therapy with sulfonamide/tri-
methoprim might be inadequate due to resistance rates of
up to 24%; therefore, it is recommended to use cipro-
floxacin instead [17]. In Austria, the rate of sulfonamide/
trimethoprim resistance is known only from local data. In
our hospital for example, the resistance rate in urinary
samples was 23.3% for sulfonamide/trimethoprim and
15% for fluoroquinolones in 2006. Fluoroquinolone
resistance in invasive E. coli isolates is high, with up to
one third of the isolates being resistant; therefore, fluoro-
quinolones can not be recommended for first-line ther-
apy. Furthermore, a study from Italy shows that resistance
to fluoroquinolones in E. coli has a negative impact on
the outcome of community-acquired urinary tract infec-
tions (UTI) and their use in this indication should there-
fore be avoided [18].
S. pneumoniae remains the most important pathogen for
community-acquired pneumoniae [19]. The susceptibility
results of invasive pneumococci indicate that penicillin G
is still very effective, since there is no upwards trend and
the number of isolates with high-level resistance is very
low (5/323). On the other hand, the macrolide resistance
rates do not show a very favourable situation: 15% of all
invasive pneumococci isolates were resistant to mac-
rolides. Compared to Germany, where up to 28% of pre-
scribed substances are narrow-spectrum penicillins [8], in
Austria, this substance group accounts for only 7% of pre-
scriptions. According to Garcia-Suarez et al., resistance
rates in invasive S. pneumoniae are lower than resistance
rates in non-invasive isolates, which is why these data
should be interpreted with care [20].
Limitations of the study
Although the increase in fluoroquinolone consumption
and the increase of fluoroquinolone resistance coincide,
which suggests an association, the results should be inter-
preted with care. For one, this is an ecological study that
considers only aggregated country data for consumption
and resistance. Another reason is that it is not possible to
make a distinction between hospital and community-
acquired infections, which might lead to overestimation
of resistance rates. Using only resistance data from hospi-
tals and not taking into account resistance data from the
community might add to any overestimation of resistance
rates. Furthermore, the lack of consumption data from the
hospital setting neglects the possible influence of hospital
prescribing on the evolution of resistance.
Conclusion
In Austria, the level of antibiotic consumption in ambula-
tory care has remained stable over the last decade. The pat-
tern of consumption, however, has changed dramatically,
with a switch from narrow- to broad-spectrum drugs, e.g.,
replacement of sulfonamide/trimethoprim with cipro-
floxacin and penicillin or amoxicillin with amoxicillin/
clavulanic acid. The Austrian resistance data can not
explain the fundamental change in prescribing practice.
The increased use of ciprofloxacin has most likely contrib-
uted to rising resistance rates in E. coli in Austria. Penicil-
lin G is still a highly effective substance for the treatment
of invasive infections caused by pneumococci.
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